The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InThe global influenza vaccine market is poised for steady growth through 2031, according to a recent report by Mordor Intelligence. Market valuation is expected to climb from USD 8.73 billion in 2025 to USD 9.38 billion by 2026. This expansion is largely driven by the dominance of quadrivalent vaccines, which held a significant 71.68% market share in 2025. Major pharmaceutical players, including Sanofi (SNY), GSK, and Pfizer (PFE), are well-positioned to benefit from the rising global demand for seasonal protection. The shift toward more advanced vaccine formulations continues to underpin the sector's long-term revenue potential. Consequently, the outlook for the healthcare sector and related ETFs like XLV remains positive as market adoption increases.